×
About 3,854,865 results

Study Finds Patients With Lung Cancer Infected With COVID-19 Are at High Risk for Hospitalization
https://ascopost.com/news/may-2020/study-finds-patients-with-lung-cancer-infected-with-covid-19-recently-treated-with-chemotherapy-at-higher-risk-of-death/

May 29th, 2020 - Data from the global TERAVOLT Consortium, which is investigating the impact of COVID-19 infection on patients with thoracic cancers, have found that these patients are at high risk for hospitalization and death. Prior use of chemotherapy was associated with an increased risk of mortality, as was the use of steroids or anticoagulants. Prior administration of immunotherapy and chemoimmunotherapy ...

First-Line Win for Anti-PD-1 Drug in Advanced Colon Cancer
https://www.medpagetoday.com/meetingcoverage/asco/86763

May 29th, 2020 - Patients with untreated heavily mutated metastatic colorectal cancer (mCRC) lived twice as long without disease progression when they received an immune checkpoint inhibitor instead of chemotherapy, a randomized trial showed.

Tepotinib Shows Activity in Patients With NSCLC and MET Exon 14–Skipping Mutation
https://ascopost.com/news/may-2020/tepotinib-shows-activity-in-patients-with-nsclc-and-met-exon-14-skipping-mutation/

May 29th, 2020 - Patients with advanced non–small cell lung cancer (NSCLC) and a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping had a 46.5% objective response rate to the targeted therapy drug tepotinib, as shown in a study presented during the ASCO20 Virtual Scientific Program (Abstract 9556) and published simultaneously by Paik et al in The New England Journal of Medicine.

Encouraging Preliminary Findings Demonstrated for Belantamab Mafodotin Combo in R/R Multiple Myeloma
https://www.targetedonc.com/view/encouraging-preliminary-findings-demonstrated-for-belantamab-mafodotin-combo-in-r-r-multiple

May 29th, 2020 - The addition of the antibody-drug conjugate belantamab mafodotin to the standard-of-care doublet of bortezomib (Velcade) and dexamethasone (B-Vd) induced a minimum response of stable disease in all patients treated in a cohort of the phase 1/2 DREAMM-6 trial.

Positive Zanubrutinib Data May Spark Change for Treatment of Waldenstrom Macroglobulinemia
https://www.targetedonc.com/view/positive-zanubrutinib-data-may-spark-change-for-treatment-of-waldenstrom-macroglobulinemia

May 29th, 2020 - A higher complete response or very good partial response (CR+VGPR) rate in patients with Waldenström macroglobulinemia (WM) was achieved with Zanubrutinib (Brukinsa), and the drug demonstrated clinically meaningful safety and tolerability, according to results of the phase 3 ASPEN trial (NCT03053440).

COVID-19-Related Mortality Risk Increases With Recent Chemotherapy in Thoracic Cancer
https://www.targetedonc.com/view/covid-19-related-mortality-risk-increases-with-recent-chemotherapy-in-thoracic-cancer

May 28th, 2020 - The risk of death in patients with thoracic cancer was inflated with the administration of chemotherapy within 3 months of a coronavirus disease 2019 (COVID-19) diagnosis, findings from the global TERAVOLT Consortium registry show.

Pharmacokinetically Guided Dose Optimization of Pazopanib Is Feasible in Daily Practice, Efficacy Not Determined
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200127/full/

May 13th, 2020 - Results from the Dutch Pharmacology Oncology Group (DPOG) therapeutic drug monitoring (TDM) study of pazopanib in patients with renal cell carcinoma (RCC) and soft tissue sarcoma (STS) demonstrated that pharmacokinetically guided dose optimization using cost-neutral interventions can be achieved in daily practice (Abstract 3598).

Dr. Lillian L. Siu Honored With 2020 International Women Who Conquer Cancer Mentorship Award
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200112/full/

May 6th, 2020 - Lillian L. Siu, MD, FRCPC, FASCO, of the Princess Margaret Cancer Centre, in Canada, has been chosen as the recipient of the 2020 International Women Who Conquer Cancer Mentorship Award. Dr. Sui is the director of the Phase I Program, co-director of the Bras and Family Drug Development Program, and clinical lead for the Tumor Immunotherapy Program. She also holds the BMO Chair in Precision Geno...

Diet and Cardiovascular Disease: The Mediterranean Diet
https://www.sciencedirect.com/science/article/pii/B9780128137925000082
The Impact of Nutrition and Statins on Cardiovascular Diseases;

Mar 1st, 2019 - Diet, lifestyle, and behavior are key modifiable risk factors for the primordial and primary prevention of cardiovascular diseases (CVD). Dietary guidelines and recommendations have positively moved from single-nutrient and food-based approaches and their impact on chronic disease to a whole of diet approach, recognizing that diet is the most modifiable risk factor for disease prevention.

Statins and the COVID-19 main protease: in silico evidence on direct interaction
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7212226/
Archives of Medical Science; Reiner Z

Apr 25th, 2020 - No proven drug and no immunisation are yet available for COVID-19 disease. The SARS-CoV-2 main protease (Mpro), a key coronavirus enzyme, which is a potential drug target, has been successfully crystallised. There is evidence suggesting that statins exert anti-viral activity and may block the infectivity of enveloped viruses. The aim of this study was to assess whether statins are potential COV...

Levodopa‐induced dyskinesia in Parkinson's disease: clinical features, pathogenesis, prevention and treatment
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2600052/
Postgraduate Medical Journal;

Jun 5th, 2007 - Levodopa is the most effective drug for treating Parkinson's disease. However, long‐term use of levodopa is often complicated by significantly disabling fluctuations and dyskinesias negating its beneficial effects. Younger age of Parkinson's disease onset, disease severity, and high levodopa dose increase the risk of development of levodopa‐induced dyskinesias (LID). The underlying mechanisms f...

New Drug Shows Promise for Levodopa-Induced Dyskinesia
https://www.parkinson.org/blog/science-news/New-Drug-Shows-Promise-for-Levodopa-Induced-Dyskinesia

People with Parkinson’s disease (PD) commonly suffer from tremors and other movement symptoms, such as slowness and stiffness, caused by the loss of dopamine-producing nerve cells in an area of the brain called the substantia nigra. The cornerstone therapy for reducing these symptoms is the drug, levodopa. Often referred to as simply L-dopa, this drug works by helping to replenish the brain’s s...

Copay cards save patients money, but come at a cost
https://www.pharmacytoday.org/article/S1042-0991(16)31400-1/fulltext

Researchers say copay coupons raise drug prices by reducing payers’ capacity to influence drug utilization when designing their formularies. Payers’ weakened position leads to higher premiums, even as consumers save money at the pharmacy counter. These conclusions appeared in studies recently published in the New England Journal of Medicine and by the National Bureau of Economic Research.

Free Drug Samples to Patients Come with Restrictions
https://www.physicianspractice.com/law-malpractice/free-drug-samples-patients-come-restrictions

The availability of pharmaceutical free samples has declined in recent years, along with the number of detailers who deliver them. According to a 2012 American Medical News report, "[p]harmaceutical companies have slashed their sales rep force by about 30 percent from a high of 105,000 five years ago, according to industry figures. And as the number of detailers has fallen, so, too, has another...

Low-cost dexamethasone reduces death by up to one third in hospitalised patients with severe respiratory complications of COVID-19
https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19

n March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK. On 8 June, recruitment to the dexamethasone arm was halted since, in the view of ...

Antiinflammatory and Antiarthritic Activities of Some Foods and Spices
https://www.sciencedirect.com/science/article/pii/B9780128138205000040
Bioactive Food as Dietary Interventions for Arthritis and Related Inflammatory Diseases;

Green herbs and seeds of fenugreek (Trigonella foenum-graecum Linn.), rhizomes of turmeric (Curcuma longa Linn.,) and ginger (Zingiber officinale Roscoe) used as foods and spices in many Asian countries are claimed to be useful in relieving pain, inflammation, and arthritis. This review describes the scientific data evaluating these claims. Fatty acids, flavonoids, saponins, alkaloids (trigonel...

Blood pressure and the new ACC/AHA hypertension guidelines
https://www.sciencedirect.com/science/article/pii/S1050173819300684
Trends in Cardiovascular Medicine;

The ACC/AHA hypertension guidelines cover virtually all aspects of the diagnosis, evaluation, monitoring, secondary causes as well as drug and non-drug treatment of hypertension. Substantial and appropriate emphasis has been given to the strategies necessary for accurate measurement of blood pressure in any setting where valid blood pressure measurements are desired.

Overdose Detection Mapping Application Program
http://www.odmap.org/

Nationally, in 2018, there were over 67,000 drug overdose deaths with opioids representing nearly 70% of all overdose deaths. 67% of all opioid-involved overdose deaths involved synthetic opioids. Data released from the Centers for Disease Control and Prevention (CDC) displays a decrease in fatal overdoses from 2017 to 2018, however, there is an absent methodology nationally to track non-fatal ...

Examination of Protein Quantity and Protein Distribution across the Day on Ad Libitum Carbohydrate and Fat Intake in Overweight Women
https://academic.oup.com/cdn/article/1/12/e001933/4772174

The effects of meal-specific protein quantity and protein distribution throughout the day on daily food intake are relatively unknown.

CURE Drug Repurposing Collaboratory
https://c-path.org/programs/cdrc/

The CURE Drug Repurposing Collaboratory (CDRC) is a public-private partnership initiated in June 2020 by C-Path and the U.S. Food and Drug Administration (FDA) in partnership with the National Center for Advancing Translational Sciences (NCATS), part of the National Institutes of Health (NIH). CDRC, in partnership with the FDA-NCATS CURE ID* platform, is a dedicated initiative designed to ca...